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https://doi.org/10.1016/j.stemcr.2018.04.002SUMMARYAlthough skeletal muscle cells can be generated from human induced pluripotent stem cells (iPSCs), transgene-free protocols include
only limited options for their purification and expansion. In this study, we found that fluorescence-activated cell sorting-purified
myogenic progenitors generated from healthy controls and Pompe disease iPSCs can be robustly expanded as much as 5 3 1011-fold.
At all steps during expansion, cells could be cryopreserved or differentiated into myotubes with a high fusion index. In vitro, cells
were amenable to maturation into striated and contractile myofibers. Insertion of acid a-glucosidase cDNA into the AAVS1 locus in iPSCs
using CRISPR/Cas9 prevented glycogen accumulation inmyotubes generated from a patient with classic infantile Pompe disease. In vivo,
the expression of human-specific nuclear and sarcolemmar antigens indicated that myogenic progenitors engraft into murine muscle to
form human myofibers. This protocol is useful for modeling of skeletal muscle disorders and for using patient-derived, gene-corrected
cells to develop cell-based strategies.INTRODUCTION
Although over 700 human genetic disorders are known
that affect skeletal muscle (Kaplan and Hamroun, 2015),
very few therapies are available. Skeletal muscle nonethe-
less has a high capacity for regeneration after injury (Bagh-
dadi and Tajbakhsh, 2017; Bursac et al., 2015; Dumont
et al., 2015). Muscle regeneration is mediated by satellite
cells (SCs) (Lepper et al., 2011; Murphy et al., 2011; Samba-
sivan et al., 2011); i.e., adult stem cells located between the
sarcolemma and the plasmamembrane (Mauro, 1961) that
are quiescent in healthy, uninjured muscle. Upon injury,
SCs expand to contribute to fiber formation and to self-
renew the SC pool.
SCs are considered useful for in vitro disease modeling to
investigate molecular mechanisms of disease, test drugs, or
develop cell-based therapies. To decipher molecular mech-
anisms of disease, it is important to generate isogenic con-
trols, given the high variability of gene expression and
functional parameters between individuals (Hockemeyer
and Jaenisch, 2016; Soldner et al., 2011). To develop cell-
based therapy, the ultimate goal is to engraft gene-cor-
rected, autologous cells. However, it has not proved easy
to date to establish robust in vitro diseasemodels for skeletal
muscle disorders, to efficiently restore gene function in
skeletal muscle cells, and to develop cell-based therapeutic
strategies based on muscle regeneration.S
This is an open access artiPluripotent stem cells (PSCs) offer a potential source of
skeletal muscle cells. PSCs, including induced PSCs (iPSCs),
are easily expanded andmaintain their full stem cell poten-
tial (Takahashi and Yamanaka, 2016). Differentiation of
PSCs to SC-like cells was difficult until the recent develop-
ment of two major strategies, the first involving the induc-
ible overexpression of PAX7, the master transcription
factor for SCs (Darabi et al., 2012). After generation from
human embryonic stem cells and iPSCs, purified SC-like
cells showed capacity for in vitro expansion and differenti-
ation, and also for in vivo engraftment and contribution to
muscle-fiber formation in immunodeficient mice (Darabi
et al., 2012; Magli et al., 2017). The second strategy
involved the use of small molecules to develop transgene-
free differentiation. After using GSK3b inhibition to
activate the Wnt pathway, the basic procedure consists of
treatment with fibroblast growth factor 2 (FGF2) and
culturing in a minimal medium (see Table S1) (Borchin
et al., 2013; Caron et al., 2016; Shelton et al., 2014, 2016;
van der Wal et al., 2017b; Xu et al., 2013). In some cases,
differentiation into the myogenic lineage has been pro-
moted by including BMP4 inhibition (Chal et al., 2015,
2016; Swartz et al., 2016). In others, FGF2has been replaced
by the Notch signaling inhibitor DAPT (Choi et al., 2016).
Transgene-free protocols can be divided into those that
use fluorescence-activated cell sorting (FACS) purification
(Borchin et al., 2013; Choi et al., 2016; van der Wal et al.,tem Cell Reports j Vol. 10 j 1–16 j June 5, 2018 j ª 2018 The Author(s). 1
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tial purification through preplating (Caron et al., 2016;
Chal et al., 2015; Shelton et al., 2014; Swartz et al., 2016;
Xu et al., 2013) (Table S1). Upon terminal differentiation
in vitro, unpurified/partially purified myogenic progenitors
showedmaturedmyotubes and evenmyofibers (Chal et al.,
2015, 2016; Swartz et al., 2016). Three reports showed
engraftment of myogenic cells from unpurified cultures
into immunodeficient mice (Choi et al., 2016; Kim et al.,
2017; Xu et al., 2013). Choi et al. (2016) reported that pu-
rification of myogenic progenitors by FACS resulted in
myogenic progenitors that could be expanded 105-fold.
Upon in vitro differentiation to myotubes, these cells also
showed a low (10%–15%) fusion index (Table S1).
In vivo engraftment of purified myogenic progenitors us-
ing a transgene-free procedure has not been reported so far.
Similarly, it has not been possible yet to expand transgene-
free, purified myogenic progenitors and differentiate and
mature these cells to myotubes with high fusion index.
Recently, we have modified a protocol by Borchin et al.
(2013) for the transgene-free differentiation of human
iPSC into SC-like cells, and used a simplified FACS purifica-
tion procedure that selects C-MET-expressing cells that
are HNK negative (Borchin et al., 2013; van der Wal
et al., 2017b). The purified cells could be expanded at least
5 3 107-fold and cryopreserved. At any point during the
expansion, cells could be differentiated into myotubes
with a high (60%–80%) fusion index. We have applied
this protocol to model Pompe disease, which is a progres-
sive inheritable metabolic myopathy caused by deficiency
of acid a-glucosidase (GAA), resulting in lysosomal
glycogen accumulation (van der Ploeg and Reuser, 2008).
This protocol allowed the quantitative analysis of the ef-
fects of antisense oligonucleotides designed to restore ca-
nonical pre-mRNA splicing of GAA in skeletal muscle cells
from Pompe patients (van der Wal et al., 2017a).
Here, we further explored the expansion capacity and the
in vitro and in vivo potential of myogenic progenitors,
generated from iPSCs in a transgene-free manner and
FACS purified, for the future development of therapies for
skeletal muscle disorders.RESULTS
Optimization of the Generation of Myogenic
Progenitors from iPSCs
As a starting point, we took the protocol published by
Borchin et al. (2013), which we had modified recently
(van der Wal et al., 2017b). This protocol consists of treat-
ing human iPSCs first with the GSK3b inhibitor
CHIR99021, then with FGF2, followed by prolonged
culturing in minimal medium. The treatment with2 Stem Cell Reports j Vol. 10 j 1–16 j June 5, 2018CHIR99021 is a critical step, as too-low concentrations
fail to yield myogenic progenitors, while too-high concen-
trations can be toxic. The optimal concentration most
likely depends on the cell culture conditions used. We as-
sume, for example, that the outcome can be affected by
culturing iPSCs with or without feeders.
In our experiments, we cultured iPSCs on g-irradiated
mouse embryonic fibroblasts. To determine the optimal
treatment with CHIR99021, we varied the concentration
and duration of treatment and scored for confluency and
PAX7 expression (Table S2). The results in two independent
iPSC lines showed that the highest number of PAX7+ cells
was induced after 4–5 days at a concentration of 4 mM
CHIR99021 in the absence of toxicity. To avoid any risk
of toxicity in subsequent experiments, we chose 5-day in-
cubation at a concentration of 3.5 mM CHIR99021.
Robustness of the Myogenic Differentiation Protocol
As outlined in Figure 1A, we used primary fibroblast-
derived iPSCs from 15 different donors, applying the
myogenic differentiation procedure in over 50 individual
differentiation experiments. Eight of these iPSC lines
were derived from healthy individuals, while seven were
from patients with Pompe disease. Figure 1B shows robust
generation of PAX7+ areas in six examples of healthy con-
trol iPSCs after 35 days of differentiation as described previ-
ously (van derWal et al., 2017b). During the differentiation
procedure, phase-contrast microscopy showed small col-
onies with a confluency of between 20% and 40% at day
1 (Figure S1A). After 5 days of culture, iPSC colonies had
reached a medium size. At this stage CHIR99021 treatment
was started. After 5 days of incubation, we observed
increased cell detachment, which was attenuated after a
further 3–4 days in FGF2-containing medium. From day
17 onwards, the cells started to proliferate rapidly, and cul-
tures reached complete confluency after 24 days. Multinu-
cleated myotube-like cells were observed between 30 and
40 days. During this differentiation procedure, we observed
similar morphological changes in all iPSC lines (Figure S1A
and data not shown).
Differentiation of 59 cultures from a total of 15 donors
yielded an average of 4.26% ± 3.96% of C-MET+/
Hoechst+/HNK-1 cells (Figure 1C). There were no signifi-
cant differences in the number of C-MET+/Hoechst+ cells
between iPSCs from healthy controls and from Pompe pa-
tients. Sorting differentiation cultures with low levels of
C-MET+/Hoechst+/HNK-1 cells (0.2% of cells) resulted
in expandablemyogenic progenitors whose differentiation
capacity was similar to that of cultures with a high recovery
(>2%) (data not shown). C-MET-/HNK-1+ cells were unable
to form myosin heavy chain (MHC)-positive cells after
4 days of differentiation (data not shown). After 24 hr of
plating, sorted myogenic progenitors revealed a rather
AB
C
Figure 1. Robustness of Generation
and Purification of Myogenic Progenitors
from iPSCs
(A) Scheme for myogenic differentiation of
iPSCs.
(B) Representative examples of PAX7+ cells
obtained in the original culture dishes from
six different control iPSC lines that were
differentiated using a 35-day protocol con-
sisting of consecutive treatment with CHIR,
FGF2, and minimal medium (Borchin et al.,
2013; van der Wal et al., 2017b). The other
two control iPSC lines showed similar
patches of PAX7+ cells (data not shown).
Red: PAX7+ nuclei using immunofluorescent
staining. Blue: nuclei stained with Hoechst.
For images of the plates during this 35-day
protocol see Figure S1A.
(C) Differentiations described in (B) were
purified using a one-step FACS purification
based on selection for C-MET+ myogenic
cells and counter selection of HNK1+ neural
crest cells (Borchin et al., 2013). Results are
shown for 59 differentiations performed on
iPSCs derived from eight healthy controls
and seven Pompe patients. Each symbol
represents an individual differentiation
experiment. Means are indicated by
horizontal lines. A total number of 24 dif-
ferentiations of control iPSCs and 35
differentiations of Pompe iPSCs were
performed.
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strated that the differentiation protocol robustly generated
C-MET+/Hoechst+/HNK myogenic cells.
InVitroExpansion, Differentiation, andMaturation of
Purified Myogenic Progenitors
During 31 days of culture we had previously determined
the proliferation rate of purified myogenic progenitors
derived from two healthy controls and two Pompe patients
(van derWal et al., 2017b). To further determine expansion
capacity, we determined the expansion capacities of
myogenic progenitors generated from iPSCs from six addi-
tional healthy controls and five additional patients with
Pompe disease. Proliferation rates were observed for all
myogenic progenitor lines that reached 2 3 1016 cells dur-
ing 43 days of expansion (Figure 2A). Cells could be cryo-
preserved with 84% recovery (Figure 2B) without affecting
differentiation capacity (data not shown), and showed
an average cell cycle of 28.9 hr (Figure 2C). After 43 days
of expansion, the proliferation rate diminished, the
morphology of cells changed, and differentiation capacity
decreased (data not shown). This showed that the
myogenic progenitors generated with this protocol could
be expanded by a maximum of 5 3 1011-fold.
Previously we had used a 4-day differentiation protocol
to demonstrate that the differentiation capacity remained
intact during the expansion phase of myogenic progeni-
tors, based on similar fusion indexes (van der Wal et al.,
2017b). Here we extended this analysis to demonstrate
that all myogenic progenitors derived from eight healthy
control and seven Pompe iPSCs retain their capacity to
differentiate into multinucleated myotubes during expan-
sion (Figure 2D). The average fusion index ranged between
20% and 97% and showed no expansion-induced differ-
ences (Figure S2A). Next, we tested whether maturation
to contractile skeletal muscle cells is possible from purified
myogenic progenitors. However, extending culture of
myogenic progenitor-derived myotubes in conventional
differentiationmedium (1% ITS-X [insulin-transferrin-sele-
nium-ethanolamine] in DMEM/F12) beyond day 4 of dif-
ferentiation increased cell detachment and death (dataFigure 2. In Vitro Expansion, Differentiation, and Maturation of
(A) Proliferation curves of myogenic progenitors derived from 15 iPSC
proliferation medium. An exponential trend line was plotted and an
liferation rates for all cell lines.
(B) Recovery of control 1 myogenic progenitors from freezing. Data a
(C) Average cell cycle duration of all cell lines shown in (A). Data are
(D) After expansion for the number of days indicated on the X axis, sk
differentiation medium. The fusion index was quantified after staining
(n = 3–5 fields per cell line) are plotted as symbols. Mean values of a
(E) At day 8 of differentiation, myotubes further matured as indicat
pattern, and spontaneous contractions (see Videos S1 and S2). Blue,not shown). Supplementation of the myogenic progeni-
tors’ differentiation medium with 0.5%–2% fetal bovine
serum increased the overall survival of the culture but
also increased the proliferation rate of mononucleated
cells, resulting in overgrowth of the cell culture (data not
shown). In contrast, supplementation with 1% knockout
serum replacement supported further differentiation of
myogenic progenitors into skeletal muscle cells for up to
12 days. Longer differentiation resulted in fibers that ex-
pressed fast MHC, MHC, titin, and a-actinin; that showed
patterns of striation (Figures 2E and S2B); and that con-
tracted spontaneously (Videos S1 and S2). This demon-
strated that functional sarcomeres, the strongest evidence
of terminal differentiation, were formed.
Generation of Gene-Corrected Myogenic Progenitors
UsingCRISPR/Cas9-Mediated Insertion of a cDNA into
a Safe Harbor
Using gene editing, it is possible to perform genetic correc-
tion of human disease in vitro by placing an extra copy of
the wild-type gene into a so-called safe harbor; i.e., a safe
location of the genome (Hockemeyer and Jaenisch,
2016). As such a strategy relies on homology-directed
DNA repair, which is inefficient, we generated a targeting
construct that allows the selection and subsequent removal
of the selection marker. The generic donor vector is shown
in Figure 3A. As a proof of concept, we chose the PPP1R12C
gene in the AAVS1 locus (Figure 3B) (Lombardo et al.,
2011). As well as unique restriction sites that enable clon-
ing of the 50 and 30 homology arms, the donor vector con-
tains a ubiquitous EF1a promoter in front of the cDNA of
interest (flanked by unique restriction sites); a poly(A)
site; and a neomycin selection marker driven by the CAG
promoter flanked by loxP sites, which provide the option
of removing the selection marker by transient expression
of CRE recombinase (Figure 3A).
As proof of principle, we aimed to correct the glycogen
accumulation caused by deficiency of lysosomal acid alpha
glucosidase (GAA) in skeletal muscle cells of Pompe pa-
tients in vitro. To this end, we cloned the native GAA
cDNA in the donor construct. iPSCs were generated fromPurified Myogenic Progenitor Cells
lines derived from healthy controls or Pompe patients, cultured in
R2 was calculated from all data points, which showed similar pro-
re means ± SD from three independent cultures.
means ± SD of all cell lines shown in (A).
eletal muscle differentiation was induced for 4 days by switching to
for MHC and Hoechst. Individual values of random fields per cell line
ll cell lines per expansion period are indicated as horizontal lines.
ed by staining for fast MHC, MHC, titin, and a-actinin, a striated
nuclei as stained with Hoechst.
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severe phenotype, which is characterized by complete defi-
ciency of GAA enzyme activity), and co-transfected the
donor vector containing the GAA cDNA with vectors
that expressed a guide RNA targeting the AAVS1 locus
and a human codon-optimized Cas9 nuclease. After selec-
tion with G418, an average of 200 colonies were obtained
per 2 3 106 cells, suggesting a targeting frequency of
1 3 104%. Twenty-nine colonies were picked and geno-
typed using two PCR strategies (Figure 3C). With PCR
primer set 1, the untargeted allele yields a product of
749 bp, while the targeted allele yields a product that is
too large to be amplified under the conditions employed.
With primer set 2, insertion of theGAA cDNA at the correct
location is detected. The results with primer set 2 showed
that 27/29 colonies had inserted the GAA cDNA at the
desired location. With primer set 1, 28/29 colonies showed
that the second allele had not been targeted. One colony
(clone 4) contained two targeted alleles. iPSCs from clone
4 were expanded, and the correct integration site was
further validated at the 30 site using primer set 3 (Figure 3D).
iPSCs from clone 4 were expanded, and myogenic progen-
itors were generated and compared withmyogenic progen-
itors from the original iPSC line before gene editing.
Myogenic progenitors from these lines were purified,
expanded, and subjected to myotube differentiation.
Similar differentiation capacities and fusion indexes were
observed before and after gene editing (Figure 3E). RT-qPCR
analysis showed the absence of GAA mRNA expression in
the untargeted Pompe myotubes; this was caused by
mRNAdecay following a frameshift in both alleles (GAA ge-
notype c.525del/c.525del). In the gene-edited myotubes,
GAA mRNA expression had been restored 5.5-fold over
levels in healthy control myotubes (Figure 3F). GAA
enzyme activity measurements showed complete restora-
tion of GAA activity in the gene-edited myotubes to levelsFigure 3. Gene Editing in iPSCs Restores the Pompe Disease Phen
(A) Generic construct for insertion of a cDNA in a safe harbor followi
(B) The construct shown in (A) was tailored to express GAA in the AA
Pompe patient, G418 selection was used, and single colonies were pi
(C) Genotyping was performed using PCR. Primer sets 2 and 3 amplifie
primer set 1 spanned the insertion site to give a product only in the a
indicating that most clones also contained an untargeted allele; with p
showed efficient targeting of at least one allele.
(D and E) (D) One clone (#4) showed targeting of both alleles, wh
myogenic progenitors for further analysis. Myogenic progenitors were
and the isogenic, gene-corrected, CI Pompe patient (CI Pompe rescue
6 days into myotubes, and the fusion index was determined (E).
(F–H) Myogenic progenitors were analyzed for GAA mRNA expressio
accumulation at day 6 (H). GAA mRNA expression was measured by R
measured using the 4-methylumbelliferone assay. Glycogen accumula
cells were cultured in glucose-free medium for the last 24 hr, as describ
two independent (healthy control) or three independent (CI Pompe disthat were3-fold higher than those of healthy control my-
otubes (Figure 3G). Myotubes from the CI Pompe patient
showed accumulation of glycogen that was restored in
the gene-edited myotubes to the levels of healthy control
myotubes (Figure 3H). Altogether, these results demon-
strate the feasibility of combining gene editing in iPSCs
with the myogenic differentiation protocol to generate
gene-corrected skeletal muscle cells.
Expression Profiling of iPSC-Derived Myogenic
Progenitors
To characterize myogenic progenitors, we used RNA
sequencing (RNA-seq) to perform genome-wide mRNA
expression analysis. Profiles from purified, expanded
(15 days) iPSC-derived myogenic progenitors from
healthy controls were compared with publicly available
datasets (see Table S3) on cell types of different lineages,
including adult SCs (FACS purified), myoblasts/myosatel-
lite cells (prepared using preplating), neuronal cells, chon-
drocytes, cardiomyocytes, hepatocytes, embryonic stem
cells, smooth-muscle cells, mesenchymal stem cells, and
fibroblasts (Figure 4A). The ‘‘new Tuxedo’’ pipeline (Pertea
et al., 2016) was used. Spearman correlation analysis
showed that profiles of two independent biological repli-
cates of myogenic progenitors from independent individ-
uals clustered together, indicating that these cells
contained similar and defined gene expression profiles
(Figure 4, myogenic progenitors from the present study
are indicated in green). The profiles of myogenic progen-
itors clustered away from all other cell types, while the
profiles of the adult quiescent and activated muscle
stem cells showed an early split from all other profiles.
A total of 1,852 out of 13,193 genes were differentially
expressed between activated muscle stem cells
and myogenic progenitors (false discovery rate < 0.01;
Table S5). The dissimilarity between quiescent andotype in Skeletal Muscle Cells In Vitro
ng CRISPR/Cas9-mediated targeting.
VS1 locus. After transfection into iPSCs from a classic infantile (CI)
cked.
d a product that is only present in correctly targeted clones, while
bsence of targeting. With primer set 1, 28/29 clones were positive,
rimer set 2, 27/29 clones were positive, indicating that most clones
ich was validated using primer set 3, and was differentiated into
generated from healthy controls, a CI Pompe patient (CI Pompe),
). Myogenic progenitors were purified, expanded, differentiated for
n at day 4 (F); GAA enzyme activity at day 4 (G); and glycogen
T-qPCR using primers spanning exon 1–2. GAA enzyme activity was
tion was measured biochemically. To deplete cytoplasmic glycogen,
ed in Bergsma et al. (2015). For (F, G, and H), data are means ± SD of
ease and rescue) cultures. Two-tailed Student’s t test: ***p < 0.001.
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primary myoblasts can be explained by the fact that the
former cells were FACS purified, while the latter cells
were obtained using preplating and probably contained
contaminating cell types. KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway analysis of genes that
were differentially expressed in myogenic progenitors
relative to activated muscle stem cells showed enrichment
of the AMPK, MAPK, and ErbB signaling pathways in
myogenic progenitors (Figure S2C). These pathways
have been involved in cell cycle regulation, muscle regen-
eration, and/or satellite cell function (Charville et al.,
2015; Golding et al., 2007; Theret et al., 2017). Overall,
this suggests that the myogenic progenitors were dissimi-
lar from the other cell types tested and contained a
defined mRNA expression profile.
To assess the purity of themyogenic progenitors, we used
the datasets shown in Figure 4A to examine the expression
of markers for pluripotent cells (POU5F1, NANOG,
and LIN28A), neuronal cells (SOX2, GFAP, and MAP2),
and chondrogenic cells (SOX5, COMP, and ACAN). None
of these markers were expressed in the purified iPSC-
derived myogenic progenitor cultures, suggesting that
contaminating cells from the lineages tested were absent
(Figure 4B).
In earlier workwe showed that, upon expansion, purified
iPSC-derived myogenic progenitors express several
myogenic markers, including the MyoD protein (van der
Wal et al., 2017b). To examine PAX7 protein expression
during in vitro expansion and differentiation, we used a
PAX7 antibody to perform immunofluorescent analysis.
Under proliferating conditions, expanded myogenic pro-
genitors (25 days) from two independent iPSCs expressed
PAX7 in a subset of cells (Figure 5A). Although myogenic
progenitor cultures contained a stable 3% of PAX7+ cells
during the majority of the expansion period, the percent-
age of Pax7+ cells started to decline at day 39 (control 1)
or day 28 (control 2) (Figure 5B). After differentiation to
myotubes, PAX7+ cells remained present in the culture (Fig-
ure 5C and data not shown). These results indicate that,
during expansion, a subset of iPSC-derived myogenic pro-
genitors continue to express markers of SCs during both
proliferation and differentiation.Figure 4. Molecular Profiling and Purity of Myogenic Progenitors
(A) Purified myogenic progenitors have a myogenic gene expression
expression (as measured by RNA-seq) from myogenic progenitors and
healthy control iPSCs were included: cells were either expanded fo
Published datasets are listed in Table S3. Datasets were analyzed usi
Spearman correlations are shown. Datasets generated in this study a
(B) Purified myogenic progenitors do not express pluripotency marker
MAP2), or chondrogenic markers (SOX5, COMP, and ACAN). Data were e
per cell line.In Vivo Myogenic Potential of Myogenic Progenitors
To test the capacity of purified and expanded myogenic
progenitors to engraft and contribute to muscle regenera-
tion in vivo, we performed cell transplantations in tibialis
anterior (TA) muscles of NSG immunodeficient recipient
mice that had been pre-injured with BaCl2. Analysis of
engraftment was performed 4 weeks after transplantation.
Using human-specific epitopes (Lamin A/C, Spectrin, and
Dystrophin; for controls, see Figure S3A), we observed
that myogenic progenitors that had been expanded for
3 days were able to engraft and participate in the formation
of new myofibers (Figure 6A). In addition, myogenic pro-
genitors were engrafted after longer periods of expansion
(6 and 11 days), and at different cell concentrations
(2.5 3 105 to 1 3 106, healthy control 1 line) (n = 6 mice)
(data not shown). Quantification of the number of Spec-
trin+ fibers showed that cell engraftment efficiency was
35–58 fibers/section, with 87–127 Lamin A/C+ nuclei/sec-
tion (Figure 6B, using two independent cell lines: control
1 and control 5). Lamin A/C+ nuclei were foundwithinmy-
ofibers and in the interstitium. A subset of Lamin A/C+
nuclei was found at a satellite cell position (Figure S3B
top); however, very few of those were Pax7+ (Figure S3B
bottom). The location of Lamin A/C+ nuclei was as follows:
45% was found within human Spectrin+ myofibers, sug-
gesting that these contributed to myofiber formation (Fig-
ure 6C); 25%–36% was found in the interstitium (Fig-
ure S3C); the remaining 23%–40% was found within
Spectrin myofibers, which may indicate that in those
(multinucleated) fibers mouse nuclei were dominant.
These results demonstrate the engraftment potential and
regenerative capacities of expanded myogenic progenitors
and their participation in muscle regeneration in vivo.DISCUSSION
In this study, we have characterized FACS-purified
myogenic progenitors for their applicability in vitro and
in vivo, and provide a detailed protocol to generate these
cells. The principle of the procedure and its possible appli-
cations are shown in Figure 7.We showed that it is possible
to reproducibly generate myogenic progenitors from 15signature. Heatmap showing a comparison of genome-wide mRNA
publicly available datasets. Purified myogenic progenitors from two
r 15 days in proliferation medium or differentiated for 4 days.
ng the ‘‘new Tuxedo’’ pipeline as described in Pertea et al. (2016).
re indicated in green.
s (POU5F1, LIN28A, and NANOG), neuronal markers (SOX2, GFAP, and
xtracted from (A). Data are means ± SD of two independent cultures
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Figure 5. PAX7 Expression during In Vitro Proliferation and Differentiation of Purified Myogenic Progenitors
(A) Purified myogenic progenitors from two healthy control iPSCs were expanded for25 days in proliferation medium and stained with a
PAX7 antibody and Hoechst to stain nuclei.
(B) Quantification of PAX7+ cells during expansion of myogenic progenitors from the two healthy control iPSCs shown in (A). Data are
means ± SD of n = 5 fields per point.
(C) Myogenic progenitors were differentiated for 6 days to myotubes. Immunofluorescent analysis was performed using a PAX7 antibody
(in red) or an MHC antibody (in red) to monitor myotube formation, as indicated. Nuclei were stained with Hoechst (blue).
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have shown previously, 4 3 104 sorted myogenic progeni-
tors could be expanded to as much as 13 1012 cells within10 Stem Cell Reports j Vol. 10 j 1–16 j June 5, 201831 days without losing differentiation capacity (van der
Wal et al., 2017b). Our current data show that the period
during which myogenic progenitors can be expanded can
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Figure 6. In Vivo Myogenic Potential of
Purified Myogenic Progenitors Following
Engraftment in Immunodeficient Mice
(A) Twenty-four hours before trans-
plantation, the TA of NSG mice was injured
using BaCl2. Myogenic progenitors were
administered using intramuscular injection
of 5 3 105 cells. Four weeks after trans-
plantation, engraftment was determined by
immunohistochemistry of human-specific
Lamin A/C and Dystrophin or Spectrin
(white or red) and multi-species Laminin
(green) on consecutive cross sections.
(B and C) (B) Quantification of Spectrin+
muscle fibers and Lamin A/C+ nuclei and (C)
the percentage of Spectrin+ fibers relative to
the total number of Lamin A/C+ nuclei per
section of each biological replicate. Data in
(B) and (C) are means ± SD (n = 2 TAs
transplanted per line used. Each replicate
was transplanted in different mice). All
sections were counterstained with Hoechst
(blue). Scale bars represent 100 mm, and
50 mm on insets.
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changes in morphology and proliferation rate suggested
the initiation of a senescent phenotype. It is therefore
likely that, during the expansion, myogenic progenitors
slowly progress to a myoblast-like phenotype, a cell
type that is known to undergo replicative senescence dur-
ing passaging (Bigot et al., 2008). After 43 days of
culture, myogenic progenitors had expanded as much as
5 3 1011-fold (the maximum value obtained), allowing
the generation of at least 2 3 1016 cells, which should be
sufficient for subsequent analyses, including high-
throughput screenings and engraftment studies.
We generated a generic donor construct that can be used
for precise and highly efficient gene correction. The selec-
tion of positive clones is facilitated by its inclusion of a se-lection marker. The option of removing the selection
marker using transient CRE recombinase expression may
be useful in future in vitro and in vivo applications. A prereq-
uisite for the strategy of inserting a wild-type copy of a
cDNA of interest is that overexpression of the transgene
product should not be harmful; if it is, the choice of
promoter that drives the transgene should be optimized.
Overexpression of a transgene is expected to benefit the
development of cell-based therapeutic strategies. In the
case of skeletal muscle, which consists of multinucleated
cells, it can be envisioned that overexpression in a subset
of engrafted myonuclei that become part of the syncytium
of the affected myofibers would cross-correct part of the
myofiber. If the transgene product is secreted, as GAA
is secreted in Pompe disease, overexpression potentiallyStem Cell Reports j Vol. 10 j 1–16 j June 5, 2018 11
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tocol. Myogenic progenitors are purified
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opreserved. During expansion, purified
myogenic progenitors are differentiated
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purified and expanded myogenic pro-
genitors form human mononuclear cells and
contribute to myofiber formation in vivo.
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sky et al., 1997).
Both iPSC-derivedmyogenic progenitors and SCs express
PAX7 during in vitro proliferation and differentiation, and
contribute to myofiber formation after intramuscular
engraftment in immunodeficient mice in vivo. We showed
that, upon optimization of the differentiation process
using defined medium conditions, the cells not only
expressed fast MHC, a-actinin, and titin but also formed
functional sarcomeres, thereby allowing spontaneous con-
tractions. These data revealed enhanced maturation
compared with that found in our previous report (van der
Wal et al., 2017b) and showed that it is possible to generate
mature myofibers from purified iPSC-derived cultures. The
formation of myogenic progenitors from Pompe patient-
derived iPSCs was not hampered by the underlying disor-
der, and we expect that this approach can be used tomodel
other disorders that affect muscle cells. It remains to be
determined whether, as Chal et al. (2015) report, purified
myogenic progenitors have the capacity to differentiate
into millimeter-long skeletal muscle cells with PAX7+ cells
embedded between the sarcolemma and the basal lamina.
It is essential for the development of stem cell-based ther-
apies that the transplantable cell preparations are highly
pure and well characterized before transplantation in hu-
man patients can be considered. The development of tech-
niques for the expansion and manipulation of pure
myogenic progenitor populations ex vivo is therefore critical
to the further development of this field. In this paper we
have provided evidence for the successful engraftment of
myogenic progenitors in pre-injured muscles of mice over
a period of 4 weeks post-transplantation. The efficiencies of
engraftment of mononuclear cells and their contribution
to myofibers were comparable with those recently obtained
using inducible PAX7 overexpression (Magli et al., 2017).
Transplantedmyogenicprogenitorsdemonstrated their abil-
ity to regenerate injuredmuscle, as was shown by the detec-
tion of centrally located laminA/C+ humannuclei, a charac-
teristic perceived only in fusion-competent myoblasts.
Future studies should identify the stem cell properties of
transplanted human myogenic progenitors that allow
transplanted donor cells to make a long-term contribution
to muscle regeneration. This would provide researchers
with novel tools that would help them make progress in
the development of muscle stem cell therapies for treating
muscle-wasting diseases.EXPERIMENTAL PROCEDURES
Ethics Approval and Consent to Participate
The Institutional ReviewBoard approved the study protocol, and all
patientsprovidedwritten informedconsent.All animalexperiments
were approvedby the animal experiments committeeDEC-Consult.Culture of Myogenic Progenitors
Myogenic progenitors were expanded in myogenitor progenitor
proliferation medium consisting of DMEM high glucose (Gibco,
Waltham, MA) supplemented with 10% fetal bovine serum (Hy-
clone, Thermo Scientific, Waltham, MA), 1% penicillin-strepto-
mycin-glutamine (P/S/G) (Gibco, Waltham, MA), and 100 ng/mL
FGF2 (Prepotech, Rocky Hill, NJ) on extracellular matrix-coated
dishes (1:200 diluted, Sigma-Aldrich, E6909). For splitting,
myogenic progenitors were detached with TrypLe reagent (Gibco,
Waltham, MA) diluted 23 with PBS (Gibco, Waltham, MA).
For cryopreservation, myogenic progenitors were detached as
described above, and after centrifugation the cell pellet was resus-
pended in myogenic progenitor proliferation medium supple-
mented with 10% DMSO. Standard cell culture techniques were
used for the freeze and thaw procedure.
RNA Isolation and RNA-Seq
Myogenic progenitors were expanded for 15 days and har-
vested either in proliferation conditions or after 4 days of differ-
entiation as described previously (van der Wal et al., 2017b).
RNA was extracted using the RNeasy minikit with DNase treat-
ment (QIAGEN, Germantown, MD). Sequencing libraries were
prepared using TruSeq Stranded mRNA Library Prep Kit
(Illumina, San Diego, CA) according to the manufacturer’s in-
structions. Libraries were sequenced on a HiSeq2500 sequencer
(Illumina, San Diego, CA) in rapid-run mode according to the
manufacturer’s instructions. Reads 50 bp in length were gener-
ated. The RNA-seq datasets listed in Table S3 were downloaded
and aligned with the datasets generated in this study using
the new Tuxedo pipeline as described by Pertea et al. (2016).
Shortly, RNA-seq data were aligned using Hisat2 (version
2.1.0) to hg38 from University of California, Santa Cruz. The
alignments were converted to BAM format using Samtools
(version 1.3.1). Then, StringTie was used to quantify transcript
expression levels according to the reference transcripts. For
KEGG analysis, gene expression was quantified using StringTie
with the -e option.
Maturation of Myogenic Progenitors into Skeletal
Muscle Cells
When myogenic progenitors reached 90% confluence, cells were
switched tomyogenic progenitor differentiationmedium contain-
ing DMEM high glucose supplemented with 1% P/S/G, 13 ITS-X,
and 1% knockout serum replacement (all Gibco). Medium was
not refreshed during differentiation and cells were harvested at
6 days, 8 days, or 12 days.
Construction of Donor Vector
To generate the generic donor vector for the overexpression of the
gene of interest via CRISPR/Cas9-mediated knockin, we used the
pCAGEN and pEF-GFP vectors (available on addgene: #11160
and #11154) as starting points. The neomycin selection cassette
was introduced via PCR amplification into the pCAGEN vector, de-
stroying the EcoRI and NotI sites. KpnI and ClaI sites were then
added to the SalI site, and loxP and SfuI sites were added to theHin-
dIII site. In the pEF-GFP vector, a KpnI site was added to the SalI site
and loxP and ClaI sites were added to the HindIII site. Vectors wereStem Cell Reports j Vol. 10 j 1–16 j June 5, 2018 13
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duced via PCR amplificationwith EcoRI andNotI fragments. The 50
homology arm of 700 bp was added via PCR amplification with
KpnI fragments, and the 30 homology arm of 972 bp was added
via PCR amplification with HindIII fragments. All constructs
were validated by sequencing. Cloning details are available on
request.
Glycogen Assay
Myogenic progenitors were differentiated for 6 days in myogenic
progenitor differentiation medium. On day 5 of differentiation,
skeletal muscle cells were starved with differentiation medium
without glucose (DMEM no glucose, Gibco). On day 6, skeletal
muscle cells were detached with a scraper and the pellet was lysed
with ice-cold protein lysis buffer (see Supplemental Experimental
Procedures). Glycogen was measured as described in Bergsma
et al. (2015).
Gene Editing of iPSCs
To select optimal target sites for the AAVS1 locus, single guide
RNA (sgRNA) sequences were designed using the CRISPRscan pro-
gram (Moreno-Mateos et al., 2015). The sgRNA CCACTAGGGA-
CAGGATTGGTGA was expressed from a TOPO vector containing
the U6 promoter (addgene: 41824). Confluent iPSCs on feeders
were pretreated 4 hr before nucleofection with 10 mM Rock inhib-
itor (Y-27632 dihydrochloride, Ascent Scientific, Asc-129). Single
cells were generated from iPSC colonies by incubating with Accu-
tase (Thermo Scientific, Waltham, MA), and 2 3 106 cells were
nucleofected with 4 mg of pCAG-hCAS9-GFP (addgene: 44719),
3 mg of TOPO-sgRNA, and 2 mg of donor vector using Amaxa Hu-
man Stem Cell Nucleofector Kit2 (VPH-5022, Lonza, Walkersville,
MD) with program B-016. After nucleofection, cells were recov-
ered in iPSC-conditioned medium (iPSC medium incubated for
24 hr on feeder cells) supplemented with 20 ng/mL FGF2 (Prepo-
tech, Rocky Hill, NJ) and 10 mM rock inhibitor. iPSCs were
selected after 48 hr of nucleofection with 100 mg/mL G-418 (In-
vivogen, San Diego, CA). Approximately 14 days after selection
of the iPSCs, single colonies were picked and genotyped using
primers from Table S4.
Transplantation into NSG Mice
NSG (Jackson Laboratories) mice aged 2–6 months were used for
transplantation studies. Mice (independently of gender) were
anesthetized with isoflurane in oxygen from a vaporizer. Regener-
ation of skeletal muscle was induced by chemical injury. The
endogenous skeletal muscle fibers of the mice were injured by in-
jection with 50 mL of 1.2% barium chloride (BaCl2) into the TA
muscle. Twenty-four hours later, 20 mL of 5 3 105 dissociated cells
were injected into the TAmuscle in duplicates (one female and one
male). Transplanted cells in this study were expanded for 3 days.
PBS-injected TAs were used as negative control for cell transplanta-
tions. Mice were sacrificed 4 weeks after cell transplantation, and
their TA muscles harvested. TA muscles were frozen in isopentane
cooled in liquid nitrogen and stored at80Cuntil analysis; 10 mm
cryosectionswere obtained at intervals throughout the entiremus-
cle and were either stored at80C for further immunostaining or
were used immediately for PAX7 staining.14 Stem Cell Reports j Vol. 10 j 1–16 j June 5, 2018Immunofluorescent Stainings
Muscle cryosections were fixed in ice-cold acetone for 5 min, fol-
lowed by a permeabilization step with 0.3% Triton X-100 in PBS
for 20 min. Samples were incubated with a blocking solution of
20% goat serum (DAKO, Santa Clara, CA) and 2% BSA (Sigma-Al-
drich, Irvine, UK) in 0.1% Tween in PBS for 1 hr. Sections
were incubatedwith primary antibodiesmouse anti-humanLamin
A/C (1:100, VP-L550, Vector Laboratories, Burlingame, CA) plus
mouse anti-human Spectrin (1:100, SPEC1-CE, Leica,Wetzlar, Ger-
many) or mouse anti-human Dystrophin (1:150, MABT827, Milli-
pore) co-stainedwith rabbit anti-Laminin (1:100, L9393, Sigma-Al-
drich, Irvine, UK) overnight at 4C. Tissue sections were stained
with secondary antibodies goat anti-rabbit (Alexa Fluor 488,
1:500, A-21141, Life Technologies, Carlsbad, CA) and horse anti-
mouse biotin (1:250, BA-2000, Vector Laboratories, Burlingame,
CA) for 1 hr at room temperature, followed by incubation with
Streptavidin 594 (1:500, S-32356, Invitrogen, Carlsbad, CA) for
30 min. Freshly cut tissue was used for PAX7 stainings. Sections
were fixed in 4% paraformaldehyde for 5 min and blocked with
20% goat serum and 2% BSA in 0.5% Triton X-100 in PBS for
1 hr, then incubated with mouse anti-PAX7 (1/20, DSHB), Lamin
A/C, and Laminin in blocking solution for 2 hr at room tempera-
ture. Goat anti-mouse IgG1 Cy3 (1:500, 115-165-205, Jackson
ImmunoResearch), goat anti-mouse IgG2b Alexa Fluor 488
(1:500, A-21141, Thermo Fisher), and goat anti-rabbit Alexa Fluor
647 (1:500, A21245, Invitrogen, Carlsbad, CA) were used in 0.1%
PBST for 1 hr. All sections were incubated with Hoechst nuclear
staining (1:15,000 Invitrogen, Carlsbad, CA) for 10 min and
mounted with Mowiol medium (Sigma-Aldrich, Irvine, UK). Im-
ages were obtained using confocal microscopy (Zeiss LSM 700).Statistical Analysis
Data represent mean ± SD, and p values refer to two-sided t tests.
Multiple groups were tested with one-way ANOVA followed by in-
dividual two-sided t tests. A p value of <0.05 was considered to
be significant. Data showed normal variance and no samples
were excluded from the analysis. Images for quantification were
randomly selected.
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